Global Paraneoplastic Pemphigus Market
Global Paraneoplastic Pemphigus Market

Paraneoplastic Pemphigus Comprehensive Study by Therapy (High Dose Corticosteroids, Steroid Sparing Agents, Others), Medication (Prednisone, Azathioprine, Ciclosporin, Cyclophosphamide, Others), Tumour (Malignant, Benign), Diagnosis Tests (Microscopy, Direct immunofluorescence testing, Indirect immunofluorescence, Assays, Other) Players and Region - Global Market Outlook to 2026

Paraneoplastic Pemphigus Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 207 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Paraneoplastic Pemphigus Market Overview:
Paraneoplastic pemphigus (PNP) is an autoimmune disorder arising from a pre-existing tumour. Paraneoplastic pemphigus is a newly recognised disease that was first recognized in 1990. It is assumed that antigens belonging to the tumour trigger an immune response resulting in blistering of the skin and mucous membranes. The earliest and most consistent symptom of this disease is severe inflammation of mucous of the mouth membrane. PNP can be mostly among the age group of 45 to 70 years old but also can be found in children and adolescents. Current treatment of Paraneoplastic Pemphigus focuses on wound healing and administering corticosteroids which has not shown a high success rate. New research developments in this field aim to treat an underlying tumour in order to heal the symptoms of PNP. Some of the players profiled in the study are Sanofi S.A. (France), Pfizer Inc. (United States), Amgen (United States), GSK Inc. (United Kingdom), Teva Pharmaceutical Industries (Israel), Novartis International AG (Switzerland), Principia Biopharma, Inc (United States) and Argenx (Netherlands).

On the basis of geography, the market of Paraneoplastic Pemphigus has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. High Dose Corticosteroids will boost the Paraneoplastic Pemphigus market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication, the sub-segment i.e. Prednisone will boost the Paraneoplastic Pemphigus market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tumour, the sub-segment i.e. Malignant will boost the Paraneoplastic Pemphigus market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Tests, the sub-segment i.e. Microscopy will boost the Paraneoplastic Pemphigus market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing World Population Results in High Occurrence of Paraneoplastic Pemphigus
  • Sufficient Medical Infrastructure in Developed Nations

Influencing Trend
  • Increasing Investment in Research of Treatment of Paraneoplastic Pemphigus

Restraints
  • High Cost Associated with Diagnosis and Medication of Paraneoplastic Pemphigus

Opportunities
  • Increasing Institutional and Government-Backed Research in Finding Cure of Paraneoplastic Pemphigus

Challenges
  • Inability to Find Complete Cure of Paraneoplastic Pemphigus
  • High R&D Costs Associated with Development of New Treatments of Paraneoplastic Pemphigus


Key Market Developments:


In Dec 2020, Amgen, a human therapeutics firm based in the US announced that the US food and drugs administration (FDA) has approved RIABNI a biosimilar to Rituxan for the treatment of adult patients with NHL, Chronic Lymphocytic Leukaemia, and other diseases. This drug is also designed to use for severe Mucocutaneous Reactions including Paraneoplastic Pemphigus which is fatal autoimmune disease caused by an immune response to functioning body part.

Paraneoplastic Pemphigus is a fatal disease and takes time to be diagnosed. The market to treat or medicate this disease is scattered and does not have any streamlined method. However, there is huge potential in treating this disease as the one player who can cure it, will make the money by licensing its technology to others. Paraneoplastic Pemphigus treating market is segmented in way of treatment, diagnosis, and containing the disease. There is no one distinct market leader in this field and the market is not matured. High R&D and expertise are essential to operate in this market.

Target Audience:
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Paraneoplastic Pemphigus Treatment Products Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Paraneoplastic Pemphigus market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Paraneoplastic Pemphigus market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Paraneoplastic Pemphigus industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Paraneoplastic Pemphigus market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Therapy
  • High Dose Corticosteroids
  • Steroid Sparing Agents
  • Others

By Medication
  • Prednisone
  • Azathioprine
  • Ciclosporin
  • Cyclophosphamide
  • Others

By Tumour
  • Malignant
  • Benign

By Diagnosis Tests
  • Microscopy
  • Direct immunofluorescence testing
  • Indirect immunofluorescence
  • Assays
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing World Population Results in High Occurrence of Paraneoplastic Pemphigus
      • 3.2.2. Sufficient Medical Infrastructure in Developed Nations
    • 3.3. Market Challenges
      • 3.3.1. Inability to Find Complete Cure of Paraneoplastic Pemphigus
      • 3.3.2. High R&D Costs Associated with Development of New Treatments of Paraneoplastic Pemphigus
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research of Treatment of Paraneoplastic Pemphigus
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Paraneoplastic Pemphigus, by Therapy, Medication, Tumour, Diagnosis Tests and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Paraneoplastic Pemphigus (Value)
      • 5.2.1. Global Paraneoplastic Pemphigus by: Therapy (Value)
        • 5.2.1.1. High Dose Corticosteroids
        • 5.2.1.2. Steroid Sparing Agents
        • 5.2.1.3. Others
      • 5.2.2. Global Paraneoplastic Pemphigus by: Medication (Value)
        • 5.2.2.1. Prednisone
        • 5.2.2.2. Azathioprine
        • 5.2.2.3. Ciclosporin
        • 5.2.2.4. Cyclophosphamide
        • 5.2.2.5. Others
      • 5.2.3. Global Paraneoplastic Pemphigus by: Tumour (Value)
        • 5.2.3.1. Malignant
        • 5.2.3.2. Benign
      • 5.2.4. Global Paraneoplastic Pemphigus by: Diagnosis Tests (Value)
        • 5.2.4.1. Microscopy
        • 5.2.4.2. Direct immunofluorescence testing
        • 5.2.4.3. Indirect immunofluorescence
        • 5.2.4.4. Assays
        • 5.2.4.5. Other
      • 5.2.5. Global Paraneoplastic Pemphigus Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Paraneoplastic Pemphigus: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GSK Inc. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Principia Biopharma, Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Argenx (Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Paraneoplastic Pemphigus Sale, by Therapy, Medication, Tumour, Diagnosis Tests and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Paraneoplastic Pemphigus (Value)
      • 7.2.1. Global Paraneoplastic Pemphigus by: Therapy (Value)
        • 7.2.1.1. High Dose Corticosteroids
        • 7.2.1.2. Steroid Sparing Agents
        • 7.2.1.3. Others
      • 7.2.2. Global Paraneoplastic Pemphigus by: Medication (Value)
        • 7.2.2.1. Prednisone
        • 7.2.2.2. Azathioprine
        • 7.2.2.3. Ciclosporin
        • 7.2.2.4. Cyclophosphamide
        • 7.2.2.5. Others
      • 7.2.3. Global Paraneoplastic Pemphigus by: Tumour (Value)
        • 7.2.3.1. Malignant
        • 7.2.3.2. Benign
      • 7.2.4. Global Paraneoplastic Pemphigus by: Diagnosis Tests (Value)
        • 7.2.4.1. Microscopy
        • 7.2.4.2. Direct immunofluorescence testing
        • 7.2.4.3. Indirect immunofluorescence
        • 7.2.4.4. Assays
        • 7.2.4.5. Other
      • 7.2.5. Global Paraneoplastic Pemphigus Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Paraneoplastic Pemphigus: by Therapy(USD Million)
  • Table 2. Paraneoplastic Pemphigus High Dose Corticosteroids , by Region USD Million (2015-2020)
  • Table 3. Paraneoplastic Pemphigus Steroid Sparing Agents , by Region USD Million (2015-2020)
  • Table 4. Paraneoplastic Pemphigus Others , by Region USD Million (2015-2020)
  • Table 5. Paraneoplastic Pemphigus: by Medication(USD Million)
  • Table 6. Paraneoplastic Pemphigus Prednisone , by Region USD Million (2015-2020)
  • Table 7. Paraneoplastic Pemphigus Azathioprine , by Region USD Million (2015-2020)
  • Table 8. Paraneoplastic Pemphigus Ciclosporin , by Region USD Million (2015-2020)
  • Table 9. Paraneoplastic Pemphigus Cyclophosphamide , by Region USD Million (2015-2020)
  • Table 10. Paraneoplastic Pemphigus Others , by Region USD Million (2015-2020)
  • Table 11. Paraneoplastic Pemphigus: by Tumour(USD Million)
  • Table 12. Paraneoplastic Pemphigus Malignant , by Region USD Million (2015-2020)
  • Table 13. Paraneoplastic Pemphigus Benign , by Region USD Million (2015-2020)
  • Table 14. Paraneoplastic Pemphigus: by Diagnosis Tests(USD Million)
  • Table 15. Paraneoplastic Pemphigus Microscopy , by Region USD Million (2015-2020)
  • Table 16. Paraneoplastic Pemphigus Direct immunofluorescence testing , by Region USD Million (2015-2020)
  • Table 17. Paraneoplastic Pemphigus Indirect immunofluorescence , by Region USD Million (2015-2020)
  • Table 18. Paraneoplastic Pemphigus Assays , by Region USD Million (2015-2020)
  • Table 19. Paraneoplastic Pemphigus Other , by Region USD Million (2015-2020)
  • Table 20. South America Paraneoplastic Pemphigus, by Country USD Million (2015-2020)
  • Table 21. South America Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 22. South America Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 23. South America Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 24. South America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 25. Brazil Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 26. Brazil Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 27. Brazil Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 28. Brazil Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 29. Argentina Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 30. Argentina Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 31. Argentina Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 32. Argentina Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 33. Rest of South America Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 34. Rest of South America Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 35. Rest of South America Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 36. Rest of South America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 37. Asia Pacific Paraneoplastic Pemphigus, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 39. Asia Pacific Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 40. Asia Pacific Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 41. Asia Pacific Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 42. China Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 43. China Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 44. China Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 45. China Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 46. Japan Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 47. Japan Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 48. Japan Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 49. Japan Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 50. India Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 51. India Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 52. India Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 53. India Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 54. South Korea Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 55. South Korea Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 56. South Korea Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 57. South Korea Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 58. Taiwan Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 59. Taiwan Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 60. Taiwan Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 61. Taiwan Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 62. Australia Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 63. Australia Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 64. Australia Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 65. Australia Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 70. Europe Paraneoplastic Pemphigus, by Country USD Million (2015-2020)
  • Table 71. Europe Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 72. Europe Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 73. Europe Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 74. Europe Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 75. Germany Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 76. Germany Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 77. Germany Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 78. Germany Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 79. France Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 80. France Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 81. France Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 82. France Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 83. Italy Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 84. Italy Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 85. Italy Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 86. Italy Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 87. United Kingdom Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 88. United Kingdom Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 89. United Kingdom Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 90. United Kingdom Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 91. Netherlands Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 92. Netherlands Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 93. Netherlands Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 94. Netherlands Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 95. Rest of Europe Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 96. Rest of Europe Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 97. Rest of Europe Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 98. Rest of Europe Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 99. MEA Paraneoplastic Pemphigus, by Country USD Million (2015-2020)
  • Table 100. MEA Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 101. MEA Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 102. MEA Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 103. MEA Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 104. Middle East Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 105. Middle East Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 106. Middle East Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 107. Middle East Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 108. Africa Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 109. Africa Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 110. Africa Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 111. Africa Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 112. North America Paraneoplastic Pemphigus, by Country USD Million (2015-2020)
  • Table 113. North America Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 114. North America Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 115. North America Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 116. North America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 117. United States Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 118. United States Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 119. United States Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 120. United States Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 121. Canada Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 122. Canada Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 123. Canada Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 124. Canada Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 125. Mexico Paraneoplastic Pemphigus, by Therapy USD Million (2015-2020)
  • Table 126. Mexico Paraneoplastic Pemphigus, by Medication USD Million (2015-2020)
  • Table 127. Mexico Paraneoplastic Pemphigus, by Tumour USD Million (2015-2020)
  • Table 128. Mexico Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Paraneoplastic Pemphigus: by Therapy(USD Million)
  • Table 138. Paraneoplastic Pemphigus High Dose Corticosteroids , by Region USD Million (2021-2026)
  • Table 139. Paraneoplastic Pemphigus Steroid Sparing Agents , by Region USD Million (2021-2026)
  • Table 140. Paraneoplastic Pemphigus Others , by Region USD Million (2021-2026)
  • Table 141. Paraneoplastic Pemphigus: by Medication(USD Million)
  • Table 142. Paraneoplastic Pemphigus Prednisone , by Region USD Million (2021-2026)
  • Table 143. Paraneoplastic Pemphigus Azathioprine , by Region USD Million (2021-2026)
  • Table 144. Paraneoplastic Pemphigus Ciclosporin , by Region USD Million (2021-2026)
  • Table 145. Paraneoplastic Pemphigus Cyclophosphamide , by Region USD Million (2021-2026)
  • Table 146. Paraneoplastic Pemphigus Others , by Region USD Million (2021-2026)
  • Table 147. Paraneoplastic Pemphigus: by Tumour(USD Million)
  • Table 148. Paraneoplastic Pemphigus Malignant , by Region USD Million (2021-2026)
  • Table 149. Paraneoplastic Pemphigus Benign , by Region USD Million (2021-2026)
  • Table 150. Paraneoplastic Pemphigus: by Diagnosis Tests(USD Million)
  • Table 151. Paraneoplastic Pemphigus Microscopy , by Region USD Million (2021-2026)
  • Table 152. Paraneoplastic Pemphigus Direct immunofluorescence testing , by Region USD Million (2021-2026)
  • Table 153. Paraneoplastic Pemphigus Indirect immunofluorescence , by Region USD Million (2021-2026)
  • Table 154. Paraneoplastic Pemphigus Assays , by Region USD Million (2021-2026)
  • Table 155. Paraneoplastic Pemphigus Other , by Region USD Million (2021-2026)
  • Table 156. South America Paraneoplastic Pemphigus, by Country USD Million (2021-2026)
  • Table 157. South America Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 158. South America Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 159. South America Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 160. South America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 161. Brazil Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 162. Brazil Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 163. Brazil Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 164. Brazil Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 165. Argentina Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 166. Argentina Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 167. Argentina Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 168. Argentina Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 169. Rest of South America Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 170. Rest of South America Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 171. Rest of South America Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 172. Rest of South America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 173. Asia Pacific Paraneoplastic Pemphigus, by Country USD Million (2021-2026)
  • Table 174. Asia Pacific Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 175. Asia Pacific Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 176. Asia Pacific Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 177. Asia Pacific Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 178. China Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 179. China Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 180. China Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 181. China Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 182. Japan Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 183. Japan Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 184. Japan Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 185. Japan Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 186. India Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 187. India Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 188. India Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 189. India Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 190. South Korea Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 191. South Korea Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 192. South Korea Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 193. South Korea Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 194. Taiwan Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 195. Taiwan Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 196. Taiwan Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 197. Taiwan Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 198. Australia Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 199. Australia Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 200. Australia Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 201. Australia Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 206. Europe Paraneoplastic Pemphigus, by Country USD Million (2021-2026)
  • Table 207. Europe Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 208. Europe Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 209. Europe Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 210. Europe Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 211. Germany Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 212. Germany Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 213. Germany Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 214. Germany Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 215. France Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 216. France Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 217. France Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 218. France Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 219. Italy Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 220. Italy Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 221. Italy Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 222. Italy Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 223. United Kingdom Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 224. United Kingdom Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 225. United Kingdom Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 226. United Kingdom Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 227. Netherlands Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 228. Netherlands Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 229. Netherlands Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 230. Netherlands Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 231. Rest of Europe Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 232. Rest of Europe Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 233. Rest of Europe Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 234. Rest of Europe Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 235. MEA Paraneoplastic Pemphigus, by Country USD Million (2021-2026)
  • Table 236. MEA Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 237. MEA Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 238. MEA Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 239. MEA Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 240. Middle East Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 241. Middle East Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 242. Middle East Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 243. Middle East Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 244. Africa Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 245. Africa Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 246. Africa Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 247. Africa Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 248. North America Paraneoplastic Pemphigus, by Country USD Million (2021-2026)
  • Table 249. North America Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 250. North America Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 251. North America Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 252. North America Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 253. United States Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 254. United States Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 255. United States Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 256. United States Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 257. Canada Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 258. Canada Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 259. Canada Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 260. Canada Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 261. Mexico Paraneoplastic Pemphigus, by Therapy USD Million (2021-2026)
  • Table 262. Mexico Paraneoplastic Pemphigus, by Medication USD Million (2021-2026)
  • Table 263. Mexico Paraneoplastic Pemphigus, by Tumour USD Million (2021-2026)
  • Table 264. Mexico Paraneoplastic Pemphigus, by Diagnosis Tests USD Million (2021-2026)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Paraneoplastic Pemphigus: by Therapy USD Million (2015-2020)
  • Figure 5. Global Paraneoplastic Pemphigus: by Medication USD Million (2015-2020)
  • Figure 6. Global Paraneoplastic Pemphigus: by Tumour USD Million (2015-2020)
  • Figure 7. Global Paraneoplastic Pemphigus: by Diagnosis Tests USD Million (2015-2020)
  • Figure 8. South America Paraneoplastic Pemphigus Share (%), by Country
  • Figure 9. Asia Pacific Paraneoplastic Pemphigus Share (%), by Country
  • Figure 10. Europe Paraneoplastic Pemphigus Share (%), by Country
  • Figure 11. MEA Paraneoplastic Pemphigus Share (%), by Country
  • Figure 12. North America Paraneoplastic Pemphigus Share (%), by Country
  • Figure 13. Global Paraneoplastic Pemphigus share by Players 2020 (%)
  • Figure 14. Global Paraneoplastic Pemphigus share by Players (Top 3) 2020(%)
  • Figure 15. Global Paraneoplastic Pemphigus share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amgen (United States) Revenue: by Geography 2020
  • Figure 23. GSK Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GSK Inc. (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2020
  • Figure 27. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 29. Principia Biopharma, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Principia Biopharma, Inc (United States) Revenue: by Geography 2020
  • Figure 31. Argenx (Netherlands) Revenue, Net Income and Gross profit
  • Figure 32. Argenx (Netherlands) Revenue: by Geography 2020
  • Figure 33. Global Paraneoplastic Pemphigus: by Therapy USD Million (2021-2026)
  • Figure 34. Global Paraneoplastic Pemphigus: by Medication USD Million (2021-2026)
  • Figure 35. Global Paraneoplastic Pemphigus: by Tumour USD Million (2021-2026)
  • Figure 36. Global Paraneoplastic Pemphigus: by Diagnosis Tests USD Million (2021-2026)
  • Figure 37. South America Paraneoplastic Pemphigus Share (%), by Country
  • Figure 38. Asia Pacific Paraneoplastic Pemphigus Share (%), by Country
  • Figure 39. Europe Paraneoplastic Pemphigus Share (%), by Country
  • Figure 40. MEA Paraneoplastic Pemphigus Share (%), by Country
  • Figure 41. North America Paraneoplastic Pemphigus Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Sanofi S.A. (France)
  • Pfizer Inc. (United States)
  • Amgen (United States)
  • GSK Inc. (United Kingdom)
  • Teva Pharmaceutical Industries (Israel)
  • Novartis International AG (Switzerland)
  • Principia Biopharma, Inc (United States)
  • Argenx (Netherlands)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation